Stocks › DBVT

DBV Technologies S.A.

DBVT·Nasdaq·USD
$9.02
-0.40 (-4.25%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
DBVT
DBV Technologies S.A. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
DBVTS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of DBVT by members of U.S. Congress · 6 on record
All congressional trades →
PoliticianStockTypeFiledTraded
James B. RenacciJames B. RenacciHouse · R · OH DBVTDBV Technologies S.A. · Stock Sale
$15,001 - $50,000
Dec 21, 2017 Dec 15, 2017 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH DBVTDBV Technologies S.A. · Stock Purchase
$1,001 - $15,000
Mar 23, 2016 Mar 8, 2016 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH DBVTDBV Technologies S.A. · Stock Purchase
$1,001 - $15,000
Feb 8, 2016 Jan 29, 2016 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH DBVTDBV Technologies S.A. · Stock Purchase
$1,001 - $15,000
Jan 27, 2016 Jan 11, 2016 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH DBVTDBV Technologies S.A. · Stock Sale
$1,001 - $15,000
Dec 21, 2015 Dec 9, 2015 Filing ↗
James B. RenacciJames B. RenacciHouse · R · OH DBVTDBV Technologies S.A. · Stock Purchase
$1,001 - $15,000
Nov 23, 2015 Nov 10, 2015 Filing ↗

Whale Activity

Position changes in DBVT reported for 2026-09-30 by 83 institutional filers
Increased: 17New: 5Held: 15Decreased: 23Closed: 20No prior filing: 3
  • Increased17
  • New5
  • Held15
  • Decreased23
  • Closed20
  • No prior filing3
FilerSharesValueChange
RA CAPITAL MANAGEMENT, L.P.3.7M$43.0Mnew
MPM BioImpact LLC3.0M$35.8Mdecreased
Siren, L.L.C.2.4M$27.7Mincreased
ADAR1 Capital Management, LLC2.0M$23.6Mincreased
Vivo Capital, LLC1.8M$21.7Mheld
Artisan Partners Limited Partnership1.6M$18.6Mincreased
BAKER BROS. ADVISORS LP1.5M$17.2Mheld
UBS Group AG1.4M$16.9Mincreased
PERCEPTIVE ADVISORS LLC1.1M$13.4Mdecreased
Patient Square Capital LP1.1M$13.0Mincreased
Octagon Capital Advisors LP574.2K$6.8Mheld
MILLENNIUM MANAGEMENT LLC553.0K$6.5Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by DBVT insiders, by quarter · Form 4
-500-25002505002025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: -4642026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

37 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Mohideen PharisChief Medical Officer Sale −464 $2.70 $1K Jul 29, 2026 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −534 n/c — Jan 29, 2026 Form 4 ↗
EPIC Bpifrance Sale −1.3M n/c — Dec 18, 2025 Form 4 ↗
EPIC Bpifrance Sale −40.0K n/c — Dec 17, 2025 Form 4 ↗
EPIC Bpifrance Sale −2.0M n/c — Dec 17, 2025 Form 4 ↗
Mohideen PharisChief Medical Officer Grant / award +44.0K $0.00 $0 Nov 21, 2025 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −1,624 n/c — Nov 21, 2025 Form 4 ↗
Trapp Kevin MichaelChief Commercial Officer Grant / award +55.0K $0.00 $0 Nov 21, 2025 Form 4 ↗
Boucinha VirginieChief Financial Officer Grant / award +32.0K $0.00 $0 Nov 21, 2025 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −6,496 n/c — Nov 20, 2025 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −464 n/c — Jul 29, 2025 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −397 n/c — May 22, 2025 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −600 n/c — Jan 30, 2025 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −565 $0.57 $322 Nov 25, 2024 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −342 $0.53 $181 Nov 22, 2024 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −2,350 $0.54 $1K Nov 21, 2024 Form 4 ↗
Mohideen PharisChief Medical Officer Grant / award +35.0K $0.00 $0 Nov 21, 2024 Form 4 ↗
Boucinha VirginieChief Financial Officer Grant / award +19.0K $0.00 $0 Nov 21, 2024 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −1,785 $0.98 $2K Jul 29, 2024 Form 4 ↗
Mohideen PharisChief Medical Officer Sale −660 n/c — May 24, 2024 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding DBVT · SEC Form N-PORT
FundSharesValue% of fundAs of
Artisan International Small-Mid Fund
Artisan Partners Funds Inc.
840.3K$13.8M0.54%Jun 30, 2026
Fidelity Advisor Biotechnology Fund
Fidelity Advisor Series VII
428.8K$5.8M0.26%Jul 31, 2026
Tax-Managed U.S. Mid & Small Cap Fund
RUSSELL INVESTMENT CO
45.1K$947K0.05%Apr 30, 2026
AdvisorShares Dorsey Wright ADR ETF
AdvisorShares Trust
43.7K$716K1.72%Jun 30, 2026
U.S. Small Cap Equity Fund
RUSSELL INVESTMENT CO
22.7K$307K0.03%Jul 31, 2026
U.S. Small Cap Equity Fund
RUSSELL INVESTMENT FUNDS
5,834$96K0.04%Jun 30, 2026
ActivePassive International Equity ETF
Trust for Professional Managers
4,402$61K0.01%Aug 31, 2026
Steward Values Enhanced International Fund
Steward Funds Inc
4,051$55K0.02%Jul 31, 2026
Lord Abbett Health Care Fund
LORD ABBETT SECURITIES TRUST
2,973$40K0.47%Jul 31, 2026
Fidelity Nasdaq Composite Index Fund
Fidelity Concord Street Trust
1,509$21K0.00%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list DBVT's shares (CUSIP 23306J309), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • MPM BioImpact LLCSCHEDULE 13G/A · passive (13G) · 15.2M shares4.8%
    Nov 13, 2026 · ↗
  • Raymond DebbaneSCHEDULE 13G/A · passive (13G) · 24.7M shares7.9%
    Nov 12, 2026 · ↗
  • Ulys, L.L.C.SCHEDULE 13G/A · passive (13G) · 1.6M shares0.5%
    Nov 12, 2026 · ↗
  • Avicenna Life Sci Master GP LLCSCHEDULE 13G/A · passive (13G) · 1.6M shares0.5%
    Nov 12, 2026 · ↗
  • Avicenna Life Sci Master Fund LPSCHEDULE 13G/A · passive (13G) · 1.6M shares0.5%
    Nov 12, 2026 · ↗
  • Siren, L.L.C.SCHEDULE 13G/A · passive (13G) · 23.1M shares7.3%
    Nov 12, 2026 · ↗
  • Invus Global Management, LLCSCHEDULE 13G/A · passive (13G) · 23.1M shares7.3%
    Nov 12, 2026 · ↗
  • Invus Public Equities Advisors, LLCSCHEDULE 13G/A · passive (13G) · 23.1M shares7.3%
    Nov 12, 2026 · ↗
  • Invus Public Equities, L.P.SCHEDULE 13G/A · passive (13G) · 23.1M shares7.3%
    Nov 12, 2026 · ↗
  • MPM BioImpact LLCSCHEDULE 13G/A · passive (13G) · 18.3M shares6.2%
    Aug 14, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming dbv technologies as client
$0$50K$100K$150K$200K2024 Q2: $40K2024 Q3: $40K2024 Q4: $40K20242025 Q1: $40K2025 Q2: $40K2025 Q3: $40K2025 Q4: $40K20252026 Q1: $30K2026 Q2: $30K2026 Q3: $30K2026
  • WINNING STRATEGIES WASHINGTONDBV TECHNOLOGIES · 2026 Q3 · HCR$30K
    Filing ↗
  • WINNING STRATEGIES WASHINGTONDBV TECHNOLOGIES · 2026 Q2 · HCR$30K
    Filing ↗
  • WINNING STRATEGIES WASHINGTONDBV TECHNOLOGIES · 2026 Q1 · HCR$30K
    Filing ↗
  • WINNING STRATEGIES WASHINGTONDBV TECHNOLOGIES · 2025 Q4 · HCR$40K
    Filing ↗
  • WINNING STRATEGIES WASHINGTONDBV TECHNOLOGIES · 2025 Q3 · HCR$40K
    Filing ↗

Government Contracts

Federal awards to DBV Technologies S.A. · USAspending

No federal contract awards found for DBV Technologies S.A..

U.S. Patents

Recent USPTO applications naming DBV Technologies S.A.

No USPTO patent applications found for DBV Technologies S.A..

Annual Financials

From DBVT's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$5.6M$4.2M$15.7M$4.8M$5.7M
Operating income-$147.1M-$116.6M-$76.4M-$96.6M-$98.6M
Net income-$146.9M-$113.9M-$72.7M-$96.3M-$97.8M
Diluted EPS-$1.05-$1.17-$0.76-$1.24-$1.78
Operating cash flow-$121.2M-$104.5M-$79.7M-$55.7M-$108.2M
Cash and equivalents$194.2M$32.5M$141.4M$209.2M$77.3M
Total assets$233.7M$65.7M$183.0M$246.5M$146.7M
Total liabilities$64.9M$38.3M$42.8M$52.1M$47.4M
Shareholders' equity$168.8M$27.4M$140.2M$194.5M$99.3M

As DBV Technologies S.A. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-5Reverse splitNov 29, 2024
  • 1-for-2Reverse splitJun 7, 2024

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsOct 28, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsSep 30, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsJul 16, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJun 29, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 9.01Officer / director changeJun 5, 2026
    EDGAR ↗
  • 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteJun 3, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 9.01Officer / director changeMay 5, 2026
    EDGAR ↗

About DBV Technologies S.A.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersCHATILLON
IncorporatedI0